FDA: Attention Deficit Meds Not Linked to Higher Risk of Serious Heart Events in Adults

Drug Industry Daily
The FDA will not change its recommendations for use of attention deficit hyperactivity disorder (ADHD) drugs, the agency said Monday, offering data from two studies that found the drugs did not increase the risk of serious adverse cardiovascular events in adults.

To View This Article:


Subscribe To Drug Industry Daily